FABP5 inhibition provides a synergistic effect in combination with chemotherapy [136], and the reported dependence of PTEN loss-driven PCa [137] on this enzyme encourages the evaluation of this therapeutic strategy in a stratified population. Here, PTEN is linked to posterior cortical atrophy.